Abstract
BACKGROUND Quantification of pancreatic fat (PF) and intrahepatic lipids (IHL) is of increasing interest in cross-sectional epidemiological and interventional studies in subjects at risk for metabolic diseases. Up to now, short- and medium-term variations as well as their dependence on actual nutritional status are almost unknown.
PURPOSE or HYPOTHESIS To assess short-term intraday variations of PF/IHL after a high-fat meal as well as medium-term changes after 5 days of high-caloric diet with a 1500 kcal surplus on individual daily energy requirement.
STUDY TYPE (retrospective/prospective/longitudinal/case control/cohort etc.) Prospective cohort study.
SUBJECTS Twelve healthy subjects (6m/6f) for intraday variations, 15 healthy male subjects for medium-term high-caloric diet and 11 age- and BMI-matched controls.
FIELDSTRENGTH/SEQUENCE 3 T whole-body imager (Magnetom Vida, Siemens Healthineers, Erlangen, Germany), assessment of proton density fat fraction by chemical-shift encoded MRI (multi-echo gradient echo sequence, qDixon).
ASSESSMENT Manually drawn regions of interest in head, body and tail of pancreas as well as in liver by an experienced medical physicist carefully avoiding inclusion of surrounding visceral fat (pancreas) or blood-vessels (liver).
STATISTICAL TESTS (please list the significance level) Repeated measurements Anova for variabilities of PF and IHL, linear correlation analyses for relation of PF, IHL and BMI. Significance level p < 0.05 for all.
RESULTS (must have numerical data and statistical testing for each phrase) Non-significant changes in PF in both studies (2.5±0.9 vs. 2.5±1.0% after high-fat meal, 1.4±0.8 vs. 1.6±0.6% after high-caloric diet and 1.6±0.7 vs. 1.8±1.0% in the isocaloric control group), unchanged IHL after high-fat meal (2.5±0.9 vs. 2.4±1.0 %) and in the control group (1.1±0.6 vs. 1.2±1.1%), but significantly increased IHL after 5-day high-caloric diet (1.6±2.2% vs. 2.6±3.6%, p < 0.05).
DATA CONCLUSION Daytime and nutritional status have no significant influence on ectopic fat depots in pancreas and liver and will therefore represent no major confounders in epidemiologic or clinical studies.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
prospective methodological study, not registered as a clinical trial but approved by the local ethics committee
Funding Statement
Supported in part by a grant (01GI0925) from the German Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD e.V.)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Both studies were approved by the ethics committee of the University Tuebingen
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Supported in part by a grant (01GI0925) from the German Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD e.V.)
Data Availability
All requests for data will be promptly reviewed by the Data Access Steering Committee of the Institute of Diabetes and Metabolic Research, Tuebingen, to verify whether the request is subject to any intellectual property or confidentiality obligations. Individual-level data may be subject to confidentiality. Any data that can be shared will be released via a Material Transfer Agreement.
